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Glucocorticoid-induced 
diabetes and adrenal 
suppression
(NOVEMBER 2011)
TO THE EDITOR: We found the article by Drs. 
Lansang and Kramer1 on glucocorticoid-
induced diabetes and adrenal suppression 
in the November 2011 issue to be a useful 
and clinically oriented review. However, we 
strongly believe there is an issue that should 
be addressed.
It is well accepted that the short cosyn-
tropin (Cortrosyn) stimulation test is the best 
screening maneuver for assessing adrenocorti-
cal insufficiency. The authors state, however, 
that 250 μg is preferable to lower doses (10 
μg or 1 μg), since these are not yet widely 
accepted, and refer to an article by Axelrod 
from 1976.2 
Based on studies showing that 250 μg of 
cosyntropin is a pharmacologic rather than a 
physiologic stimulus that may overstimulate 
partially atrophied or mildly dysfunctional 
adrenal glands, multiple studies in the last 
20 years have shown that the low-dose test 
has an equal or better result than the classic 
250-μg dose test.3 Dorin et al,4 in a meta-
analysis of the diagnosis of adrenocortical 
insufficiency that included more than 30 
studies, found similar sensitivity and specific-
ity in primary and secondary adrenal insuffi-
ciency comparing the 250-μg dose vs the low 
dose. In cases of mild primary adrenal failure, 
the low-dose test has better performance. A 
previous investigation in our research center 
contrasting 250 μg vs 10 μg proved that 10 
μg had a better sensitivity than the standard 
dose, with excellent reproducibility and in-
terchangeability.5 Similar findings have been 
shown by other authors contrasting 1 μg vs 
250 μg of cosyntropin.6
We believe that the limited use of the 
low-dose cosyntropin test is not a matter 
of acceptance or performance but a conse-
quence of the lack of vials containing lower 
doses of cosyntropin (1 to 10 μg), which 
makes this test technically challenging.2,4 
The steps needed for one-dose testing and 
the preservation time of the preparation are 
strong limitations to its wide use in clinical 
practice and endocrine laboratories.
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TO THE EDITOR: Drs. Lansang and Hustak1 provide 
a comprehensive and useful review of steroid-
induced diabetes and adrenal suppression. 
In their section on local steroids, they 
discuss the side effects of topical and inhaled 
glucocorticosteroids. Much has been made of 
the fact that certain steroids, such as mo-
metasone (Elocon, Nasonex) and fluticasone 
(Flonase), have a higher “therapeutic index” 
or ratio of local anti-inflammatory effect to 
systemic side effects, due to extensive hepatic 
first-pass metabolism, than older agents such 
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as beclomethasone (Qvar) and betametha-
sone (Diprosone).2 Ciclesonide (Alvesco, 
Omnaris), a newer inhaled steroid, is said to 
have an enhanced therapeutic index because 
it is a prodrug that is activated by metabolism 
in the lungs; it reportedly has an even less 
suppressive effect on hypothalamic-pituitary-
adrenal axis function.3 
Are the authors aware of any other evidence 
that clinical outcome, such as adrenal suppres-
sion or hyperglycemia, is improved by the use of 
steroids with a higher therapeutic index?
dAVid L. KeLLeR, Md
Providence Medical group 
torrance, CA
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IN REPLY: We thank Drs. Rodríguez-Gutiérrez 
and Gonzálvez-Gonzálvez and Dr. Keller for 
their thoughtful comments.
In our paper, we did not elaborate on the 
low-dose cosyntropin stimulation test.  The 
1-µg test, in particular, has been shown to 
have similar or better sensitivity, with similar 
or lower specificity, compared with the 250-µg 
dose, depending on the study design. Unfor-
tunately, the administration of the 1-µg dose 
presents more technical difficulty than the 
250-µg dose, thus limiting its use. Cosyntropin 
(used in the United States) comes in a vial 
with 250 µg of powder. This must be reconsti-
tuted with 250 mL of normal saline, and only 
1 mL is to be given. Adherence to the plastic 
tubing may occur, and more precise timing is 
needed as the cortisol levels may decrease.1–3
Responding to Dr. Keller, we were un-
able to find any systematic reviews comparing 
inhaled corticosteroids that have a “higher 
therapeutic index” as a class vs older inhaled 
corticosteroids. There are several studies, 
however, comparing individual inhaled corti-
costeroid preparations with each other in terms 
of adrenal effects, and we feel that it is beyond 
the scope of this response to perform a system-
atic analysis. In addition, the determination 
of adrenal function used in studies comparing 
one inhaled corticosteroid with another were 
varied, including cosyntropin stimulation tests 
and surrogates such as the urinary cortisol-
creatinine ratio, a morning plasma cortisol level 
less than 5 µg/L, and serum cortisol concentra-
tion curves, preventing more definitive con-
clusions even if the data were to be pooled.4–6 
A double-blind, randomized study comparing 
the adrenal effects of ciclesonide and flutica-
sone showed a smaller reduction in the peak 
serum cortisol level achieved with ciclesonide 
compared with fluticasone, in both low-dose 
and high-dose cosyntropin stimulation tests, 
with the results in the ciclesonide group being 
similar to placebo.7 However, the mean peak 
serum cortisol levels after exposure to these 
inhaled corticosteroids were not presented in 
table format, and the results have to be inferred 
from the figures and the narrative description of 
the baseline mean peak cortisol levels8 (ie, be-
fore exposure to these inhaled corticosteroids). 
Case reports have suggested that changing the 
inhaled corticostseroid formulation from fluti-
casone to ciclesonide allowed for improvement 
of adrenal function.8 The purported mechanism 
of decreased adrenal effects of ciclesonide is its 
greater deposition in the lungs and, hence, less 
entry into the systemic circulation and fewer 
systemic adverse effects.9
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Essential tremor, 
beta-blockers, and calcium 
channel blockers
(DECEMBER 2011)
TO THE EDITOR: In their thorough review of essen-
tial tremor,1 Drs. Abboud, Ahmed, and Fer-
nandez make a statement that needs clarifica-
tion. In their list of absolute contraindications 
to propranolol (Inderal), the authors include 
“concurrent use of a calcium channel blocker.” 
This warning applies only to the nondihydro-
pyridine calcium channel blockers, which are 
diltiazem (Cardizem) and verapamil (Calan). 
These two medications slow the heart rate 
and generally should not be combined with 
beta-blockers such as propranolol unless the 
patient requires this combination to control 
tachycardia. Most calcium channel blockers 
are dihydropyridines, which include amlodip-
ine (Norvasc), nifedipine (Procardia), felodip-
ine (Plendil), nisoldipine (Sular), isradipine 
(DynaCirc CR), and nicardipine (Cardene). 
These agents do not slow the heart rate sig-
nificantly and therefore can be used freely in 
combination with propranolol. Of course, the 
dose of the calcium channel blocker may need 
to be decreased because of the antihyperten-
sive effect of propranolol.
dAVid L. KeLLeR, Md 
Providence Medical group 
torrance, CA
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IN REPLY: We agree and thank Dr Keller for 
raising this valid point. The two classes of 
calcium channel blockers are distinct in 
their actions, and the warning about not 
combining a calcium channel blocker with 
a beta-blocker because of the increased risk 
of developing significant bradycardia applies 
only to the nondihydropyridine class.
HeSHAM ABBoud, Md 
Cleveland Clinic
AnwAR AHMed, Md 
Cleveland Clinic
HuBeRt H. FeRnAndez, Md 
Cleveland Clinic
doi:10.3949/ccjm.79c:04005
Parkinson disease
(JANUARY 2012)
TO THE EDITOR: I have the following comments 
and questions regarding the excellent Medical 
Grand Rounds article on Parkinson disease by 
Dr. Fernandez in your  January 2012 issue.1
The author mentions that when “cost may 
be of concern, levodopa is the preferred start-
ing drug.”1 Generic versions of pramipexole 
and ropinirole are now available and have 
made these medications more affordable. For 
example, the cash price of generic ropinirole 
5 mg was recently $66 for 100 tablets, compa-
rable with generic carbidopa/levodopa (25/100 
mg priced at $46 for 100 tablets.2 And even 
though the price of generic pramipexole was 
$240 for 90 tablets, seniors with Medicare Part 
D drug coverage can usually get any generic 
medication for a low copay.
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When choosing a dopamine agonist, how 
does Dr. Fernandez decide between ropinirole 
and pramipexole (aside from the price differ-
ence noted above)? Pramipexole has a longer 
elimination half-life (8 to 12 hours) compared 
with ropinirole (6 hours).3 Does this imply a 
significantly longer effective dosing interval 
for pramipexole? Are there other significant 
clinical differences between these agents?
Isradipine (DynaCirc CR), a dihydro-
pyridine calcium channel blocker, has shown 
promise as a neuroprotective agent for slow-
ing the progression of Parkinson disease in 
epidemiologic and laboratory studies, as noted 
by the author. In addition, immediate-release 
isradipine, with its relatively short elimina-
tion half-life of 8 hours,3 may be well suited 
for treating Parkinson patients whose essential 
hypertension is complicated by episodes of or-
thostatic hypotension. It should be noted that 
dihydropyridines that do not cross the blood-
brain barrier (such as amlodipine [Norvasc]) 
have shown no evidence of neuroprotection.
Ibuprofen is another drug that has fairly 
strong epidemiologic and laboratory evidence 
that it might be neuroprotective,4 although 
the other nonsteroidal anti-inflammatory 
drugs (NSAIDs) have proven disappointing as 
a class.5 Lacking any prospective randomized 
trials, the evidence is not strong enough to 
recommend ibuprofen solely for neuroprotec-
tion. Does Dr. Fernandez, however, consider it 
reasonable to suggest ibuprofen to Parkinson 
patients who need to take an NSAID for an 
approved indication (such as pain)?
Dexpramipexole has recently demonstrat-
ed great promise in a phase 3 clinical trial as a 
neuroprotective agent in amyotrophic lateral 
sclerosis.6 How does this compound relate to 
pramipexole, and does the author believe it 
may offer neuroprotection in other neurode-
generative diseases like Parkinson disease?
The author discusses the use of catechol-
O-methyltransferase (COMT) inhibitors 
(such as Comtan and Tasmar) and the mono-
amine oxidase (MAO) type-B inhibitors 
rasagiline (Azilect) and selegiline (Eldepryl, 
Zelapar) for prolonging the effects of levodo-
pa by slowing the breakdown of dopamine. 
However, it is important to note that it is 
contraindicated to prescribe both a COMT 
inhibitor and an MAO-B inhibitor, because 
these agents also inhibit the breakdown of 
other catecholamines and can lead to adren-
ergic crisis when taken concomitantly. 
dAVid L. KeLLeR, Md 
Providence Medical institute 
torrance, CA
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IN REPLY: I thank Dr. Keller for his thoughtful 
comments. They are most appreciated.
It is true that with availability of generic 
ropinirole and pramipexole, there are now 
cheaper alternatives to levodopa. Nonetheless, 
levodopa remains the cheapest and most effica-
cious medication for Parkinson disease to date. 
Whenever levodopa is compared head-to-head 
with any dopamine agonist, the general results 
remain consistent: levodopa affords better 
motor improvement with lesser side effects, 
but is more likely to lead to motor fluctuations, 
specifically dyskinesias. Therefore, in general, 
levodopa is the first choice in elderly patients 
where tolerability may be an issue, whereas a 
dopamine agonist may be the initial treatment 
of choice in younger Parkinson patients, who 
are able to tolerate the drug better and have a 
higher likelihood of developing dyskinesias. 
It is a tougher task to determine which 
among the dopamine agonists is superior. The 
newer dopamine agonists have not been com-
pared head-to-head. Therefore, it is practically 
a “coin toss” when selecting which dopamine 
agonist to try. Their mechanism of action (D2 
and D3 receptor agonist activity) and frequen-
cy of intake (three times per day for generics; 
once daily for long-acting formulations), cost, 
and side effect profile are nearly identical, 
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despite minor differences in their half-lives. 
Regarding putative neuroprotective 
agents in Parkinson disease, indeed, isra-
dipine is one of the medications currently 
undergoing investigation for its potential 
neuroprotective effect. While I personally 
have no objection to using it for a Parkinson 
disease patient who also happens to need 
an antihypertensive agent, I am more cau-
tious about endorsing it as a neuroprotective 
agent until results of clinical trials have been 
released. Similarly, while a large epidemio-
logic study has shown that people who take 
ibuprofen are less likely to develop Parkinson 
disease, there has been no robust human trial 
that has shown the drug to slow the progres-
sion of Parkinson disease among patients 
who are already suffering from the disorder. 
Therefore, the current use of ibuprofen in 
Parkinson disease should be based more on 
its anti-inflammatory indications rather than 
its possible neuroprotective effect. Finally, we 
have shown, in a large, multicenter, global 
randomized controlled trial with a delayed-
start design, that pramipexole is unlikely 
to possess any meaningful neuroprotective 
effect. Therefore, I am personally not that 
optimistic that dexpramipexole would dem-
onstrate such an effect. 
While in theory combining the use of 
catechol-O-methyltransferase (COMT) in-
hibitors and monoamine oxidase (MAO) type 
B inhibitors can synergistically work to inhibit 
the breakdown of other catecholamines and 
lead to adrenergic crisis when taken concomi-
tantly, this has not been our experience. Per-
haps it is because at recommended doses, the 
MAO inhibition is selective to type B (where 
receptors are more confined to the brain) and 
not type A (where receptors are more distrib-
uted throughout blood vessels, thereby having 
a higher likelihood of causing a hypertensive 
crisis as is seen in the use of nonselective 
MAO inhibitors). Therefore, at our center, we 
routinely use the two classes of agents con-
comitantly with minimal safety concerns.
HuBeRt H. FeRnAndez, Md 
Cleveland Clinic Lerner College 
of Medicine 
Center for neurological Restoration 
Cleveland Clinic
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